A series of 4′-C-(hydroxymethyl) analogs of pyrimidine and purine nucleosides have been prepared utilizing standard methodologies, and the α and β anomers were separated. These analogs are part of our continuing efforts to identify new anticancer drugs as well as to explore the substrate specificities of these analogs with the initial activating enzymes in the metabolic pathway leading to nucleoside triphosphates. Although not cytotoxic to CCRF-CEM cells (an acute lymphoblastic leukemia of T-cell origin), many of these compounds were utilized as substrates for the various human nucleoside kinases, including deoxycytidine kinase, thymidine kinase 1, and thymidine kinase 2. Because the 4′-C-(hydroxymethyl) analog of arabinofuranosyl cytosine was identified as a good substrate with deoxycytidine kinase, its metabolism in CEM cells was evaluated. These results indicated that nucleosides with this modification could be activated in human cells without cytotoxicity, which suggested that they should be examined for antiviral activity.
Interest in 4′-substituted nucleosides dates back to the early work of Moffatt, Verheyden and others 1 . Since that time a large number of 4′-substituted nucleosides have been prepared and some of them have been found to have interesting biological activity [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] . Compounds that have been found to have some cytotoxicity include 2′-deoxynucleosides with α-4′-C-methyl 3, 11 , cyano 3, 13 , ethynyl 2, 4, 13 , ethenyl 2 and fluoromethyl 19 groups. In our laboratory we have focused for many years on the development of new nucleosides with anticancer activity, including recently several series of compounds that have 4′-C-substitution. In addition, we have focused on other substitution patterns and other carbohydrate configurations as we explore what changes are allowed by the initial activating enzymes, typically deoxycytidine kinase, thymidine kinase and guanosine kinase. One of the first groups that was of interest was the α-4′-C-(hydroxymethyl) group because it had the potential of offering a second site for initial phosphorylation in the metabolism of a nucleoside analog up to the triphosphate level. Many 4′-C-(hydroxymethyl)nucleosides have been prepared, including analogs with β-D-xylo, ribo and 2′-deoxyribo configurations 1, [23] [24] [25] [26] [27] [28] , as well as analogs of AZT, d4T, ddT prepared as potential antiviral agents 29, 30 . We report herein the synthesis of a series of 4′-C-(hydroxymethyl)-α-and -β-D-threo-pentofuranosyl pyrimidine and purine nucleosides 31 . These target compounds are additional examples of 4′-derivatives of arabinonucleosides. The newly synthesized compounds have been examined for their cytotoxicity as well as for their ability to serve as substrates for the appropriate initial activating kinases.
Chemistry
Our synthetic approach to the target hydroxymethyl-substituted nucleosides follows generally along standard lines. The suitably protected carbohydrate 10 was prepared in 13 steps from L-xylose (Scheme 1). 1,2-O-Isopropylidene-α-L-xylo-furanose intermediate 1 was prepared from L-xylose following the procedure described by Gosselin et al. 32 in 94% yield. Selective benzoylation of the 5-hydroxyl group of 1 with benzoyl chloride in dry pyridine at 0°C was performed in 77% yield and was followed by the protection of the 3-hydroxy group by reaction with tert-butyldimethylsilyl chloride (TBDMSCl) in dry pyridine at room temperature to give compound 3 in quantitative yield. The 5-position of 3 was debenzoylated with sodium methoxide in a methanol/toluene mixture in 88% yield and subjected to an oxidation. Oxidation of the 5-position of 4 was performed under Pfitzner-Moffatt conditions 33, 34 , with dimethyl sulfoxide (DMSO), dicyclo- hexylcarbodiimide (DCC) and dichloroacetic acid and led to the pentodialdofuranose intermediate 5 which was subsequently converted to the 4-C-(hydroxymethyl) derivative 6.
Our approach of the synthesis of 6 was based upon the precedent established by Schaffer 35, 36 and Moffatt and co-workers 24, 25 , utilizing an aldol condensation-crossed Cannizzaro reaction sequence between a suitably protected pentodialdofuranose and formaldehyde in aqueous sodium hydroxide. When the 3-O-(tert-butyldimethylsilyl)-1,2-O-isopropylidene-α-L-xylo-pentodialdo-1,4-furanose intermediate 5 was subjected to the aldol condensation-crossed Cannizzaro reaction sequence, introduction of the hydroxymethyl group was accompanied by loss of the 3-O-tert-butyldimethylsilyl group 2 but without any epimerisation at C-3 17 . 
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SCHEME 1
The three hydroxy groups of 6 were then protected by reaction with benzyl chloride in the presence of sodium hydride and tetrabutylammonium iodide in THF to afford compound 7 in 91% yield. Cleavage of the isopropylidene group of 7 with 85% acetic acid and concentrated sulfuric acid followed by methylation of the anomeric hydroxyl group with methanol and sulfuric acid afforded 8 in 95% yield. The last OH group of 8 was benzylated under the same condition described above to give the tetra-O-benzylated derivative 9 in 92% yield. Hydrolysis of the methyl glycoside 9 with 90% trifluoroacetic acid followed by acetylation of the anomeric OH with acetic anhydride in dry pyridine afforded the desired intermediate 10.
As representative nucleoside targets, we chose 12, 14, 16, 18, 20, and 22, both the α and β anomers. Again, standard routes were utilized to prepare the twelve target compounds, though slightly different conditions were utilized for pyrimidines versus purines.
To prepare the 4-oxopyrimidine nucleosides (Scheme 2), blocked precursor 10 was respectively condensed with the commercially available uracil, thymine or 5-fluorouracil, under Vörbruggen 37 conditions using trimethylsilyltrifluoromethanesulfonate (TMSOTf) as a catalyst, to give the fully corresponding benzylated nucleosides as an α:β mixture, separable by silica gel chromatography, in 90% yield (α/β 1.8:1) for the uracil nucleosides 11␣, 11␤, 87% yield (α/β 3.3:1) for the thymine nucleosides 13␣, 13␤, and 88% yield (α/β 1.4:1) for 5-fluorouracil nucleosides 15␣, 15␤. Finally, benzyl ether protective groups of 11␣, 13␣, 15␣ and 11␤, 13␤, 15␤ were cleaved by catalytic hydrogenation in good yields to give target compounds 12␣, 14␣, 16␣ and 12␤, 14␤, 16␤.
In order to generate cytosine nucleoside analogs (Scheme 2), conversion of benzylated uracil and 5-fluorouracil derivatives 11␣,␤ and 15␣,␤ into the corresponding cytosine and 5-fluorocytosine nucleosides 17␣,␤ and 19␣,␤ was carried out via a treatment with Lawesson's reagent 38, 39 which led to the 4-thioamide derivatives, followed by a treatment with methanolic ammonia at 100°C in a stainless-steel bomb. This transformation was performed in quantitative yield for 17␣, 82% yield for 17␤ and 90% yield for 19␣, 19␤. Finally, benzyl ether protective groups of 17␣, 19␣ and 17␤, 19␤ were cleaved with a boron trichloride solution in anhydrous dichloromethane in good yields to give target compounds 18␣, 20␣ and 18␤, 20␤.
In order to prepare the two adenine nucleoside anomers 24␣ and 24␤ (Scheme 3), condensation of 10 with silylated 6-chloropurine was performed at room temperature in the presence of tin(IV) chloride in anhyd- rous acetonitrile and afforded in 74% yield a 1.8:1 mixture of N-7 and N-9 isomers (21␣␤ and 22␣␤). After separation by silica gel chromatography N-7 isomer (21␣␤) was converted to the N-9 isomer (22␣␤) in 54% yield by treatment with TMSOTf in acetonitrile at room temperature. Separation of 22␣ and 22␤ (α/β 0.8:1) was performed by silica gel chromatography. Displacement of the chlorine atom at the 6-position of compounds 22␣ and 22␤ was performed with ethanolic ammonia at 75°C in a stainless-steel Griffon et al.: 
SCHEME 3
bomb in 94 and 82% yields, respectively. Finally, benzyl ether protective groups of 23␣ and 23␤ were cleaved by hydrogenation using Pd(OH) 2 as catalyst under 50 Pa of H 2 to give target compounds 24␣ and 24␤ in 66 and 49% yields, respectively.
Biological Results
The target compounds were prepared as 4′-substituted arabinonucleoside analogs, and they are referred to in that manner. Thus, the cytosinecontaining target 18␤ can be considered to be 4′-C-(hydroxymethyl)-ara-C, abbreviated HM-araC below.
None of the 4′-C-(hydroxymethyl)-substituted target nucleosides was cytotoxic to CEM cells at a concentration of 40 µg/ml. The 4′-C-hydroxymethyl compounds were evaluated as appropriate as substrates with thymidine kinase 1, thymidine kinase 2, deoxycytidine kinase and deoxyguanosine kinase to determine whether or not they could be phosphorylated in human cells (Table I ). The uracil, thymine and adenine analogs were poor substrates for their respective kinases, which suggested that their lack of cytotoxicity was due to their lack of conversion to cytotoxic nucleotides. However, the β isomers of the two cytosine analogs were phosphorylated by dCyd kinase. The K m values for 2′-deoxycytidine (dCyd), HM-araC (18␤) and 5-F-HM-araC (20␤) with the recombinant enzyme were 1.0 ± 0.3, 18 ± 6, and 32 ± 19 µM, respectively, and K cat values for these agents were 0.11 ± 0.02, 0.07 ± 0.01, and 0.11 ± 0.02 s -1 , respectively. The catalytic efficiency of HM-araC with this enzyme was 14% of that seen with dCyd.
Because of the activity of the cytosine analogs with the recombinant dCyd kinase, the metabolism [ 3 H]HM-araC was studied in CEM cells. In our initial studies using our standard SAX HPLC system 40 , there was a linear increase in a metabolite in CEM cells that eluted at 20 min (data not shown). This metabolite eluted with a retention time that was similar to that of dCTP and is therefore likely to be the 5′-triphosphate of HM-araC (HM-araCTP). Because there was considerable increase in radioactivity in the void of this SAX HPLC column, the samples were analyzed using BioBasic HPLC, which retains monophosphates better than our standard SAX HPLC system. Using this system it was clear that HM-araC was converted to 2 metabolites (Fig. 1) . The addition of dCyd (100 µM) to the incubations with HM-araC completely inhibited the formation of both metabolites, and neither metabolite was formed in CEM cells that were deficient in dCyd kinase (data not shown). The peak eluting at 8 min was de-termined to be HM-araC by spiking the sample with [ 3 H]HM-araC. The 5′-phosphate of HM-araC (HM-araCMP) was created by incubating HM-araC with dCyd kinase that had been purified from CEM cells and ATP, and the peak of radioactivity that eluted at 24 min in Fig. 1 eluted with this HM-araCMP standard. The peak eluting at 36 min is HM-araCTP, based on its elution with dCTP in the first SAX HPLC column. The rate of conversion of 10 µM dCyd to dCTP in CEM cells was 0.91 pmol/10 6 cells/min, whereas the rate of conversion of 10 µM HM-araC to HM-araCMP and HM-araCTP in CEM cells was 0.01 pmol/10 6 cells/min, which indicated that the rate of activation of HM-araC in CEM cells was approximately 100-fold less than that of dCyd. 
The phosphoryl transfer assays were performed as described in the Biological Materials and Methods. The final concentration of each nucleoside was 100 µM and the values (mean and standard deviations of three determinations) represent percent activity compared to either dThd or dCyd. nd, not done. were incubated with 10 µM [ 3 H]HM-araC (1 µCi/ml). Cells were collected from 15 ml of culture and the amount of HM-araCMP and HM-araCTP were determined as described in the legend to Fig. 1 There was a considerable accumulation of HM-araCMP in CEM cells, which indicated that the rate of its synthesis was much greater than the rate of its use as a substrate by the monophosphate kinase (Fig. 2) . At early time points the predominant intracellular metabolite was HM-araCMP. However, by 6 h the intracellular concentration of HM-araCTP was equal to that of the monophosphate (Fig. 2 ). This result indicated that HM-araCMP was a relatively poor substrate for CMP kinase.
With a partially pure preparation of dCyd kinase from CEM cells we compared the rate of phosphorylation of dCyd and HM-araC using both ATP and UTP as the phosphate donor (Table II) . With ATP as the phosphate donor the HM-araC was phosphorylated at a rate that was 0.7% of that seen with dCyd, and with UTP the rate of HM-araC phosphorylation was 6% of that of dCyd. These results are in general agreement with the intact cells studies and indicate that HM-araC was only a modest substrate for dCyd kinase isolated from CEM cells. The kinetic data with the recombinant enzyme indicates that the phosphorylation with HM-araC at 10 µM would be 15% of that of dCyd. Previous studies in our laboratory 41 indicate that the phosphorylation of 10 µM araC by dCyd kinase isolated from CEM cells would be similar to that of dCyd using both UTP and ATP as the phosphate donor. Therefore, these results indicate that HM-araC is approximately 100-fold less efficient as a substrate for dCyd kinase than araC.
HM-araC was not toxic to CEM cells. The concentration of HM-araC required to inhibit growth by 50% during a 96-h incubation was greater than 150 µM. Although the metabolism is not as great as that seen with araC, a considerable amount of HM-araCTP was formed in CEM cells, which suggested that HM-araCTP was poorly recognized by the human DNA polymerases involved in DNA replication. Since HM-araCTP was formed in cells without toxicity, this result suggests that this compound should be examined for antiviral activity.
EXPERIMENTAL
Biological Materials and Methods
Determination of cytotoxicity. CCRF-CEM cells (obtained from the American Type Culture Collection) were grown in RPMI 1640 medium (Gibco-BRL) containing 10% of fetal bovine serum (Atlanta Biologicals), 10 U/ml of penicillin, 10 µg/ml of streptomycin, and 50 µg/ml of gentamycin. The cells were exposed continuously to various concentrations of the compounds at 37°C for 72 h, and cell numbers were determined with a Coulter Counter.
Measurement of nucleoside kinase activity with recombinant nucleoside kinases. The recombinant human enzymes dThd kinase 1, dThd kinase 2, and dCyd kinase were expressed and purified from the bacterial expression system according to the procedures described previously 42 without removal of the histidine tag sequences. The enzymes were at least 95% pure as judged by SDS-PAGE. dThd kinase 1 and dThd kinase 2 had specific activities of 17 and 70 nmol/min/mg protein, respectively, using dThd as substrate. The specific activity of dCyd kinase was 18 nmol/min/mg using dCyd as substrate. The assays were performed as described previously 42 with minor modifications. The reaction mixtures contained final concentrations of 100 µM of nucleosides, 100 µM was used to analyze the phosphorylated metabolites of HM-araC, because of its superior retention of mononucleotides. Elution of nucleotides with this column was accomplished with 30-min linear salt and pH gradient from 6 mM ammonium phosphate (pH 2.8) to 900 mM ammonium phosphate (pH 6) with a flow rate of 2 ml/min. Radioactive metabolites of HM-araC were detected by counting 1-min fractions that eluted from the column. Natural nucleotides were detected by their absorbance at 260 nm. 
To anhydrous acetone (1 l) were successively added 97% sulfuric acid (5 ml), anhydrous copper sulfate (100 g) and L-xylose (50 g, 0.33 mol). The mixture was stirred at room temperature for 24 h with exclusion of moisture and filtered. The filtrate was neutralized with 20% ammonium hydroxide (35 ml), filtered and evaporated to dryness under reduced pressure.
The residue was then co-evaporated several times with absolute ethanol to afford 1,2:3,5-di-O-isopropylidene-α-L-xylofuranose as a syrup, only contaminated with a trace of 1.
To this syrup, aqueous 0.2% hydrochloric acid (440 ml) was added and the mixture was stirred at room temperature for 3 h and neutralized with solid sodium hydrogencarbonate. The solution was evaporated to dryness under reduced pressure and the crude material was dissolved in chloroform (200 ml), dried over anhydrous sodium sulfate and evaporated under reduced pressure to give pure 1 as a yellow syrup (59.1 g, 94% 
A solution of 1 (59.1 g, 0.31 mol) in anhydrous pyridine (400 ml) was stirred under argon and cooled to 0°C. A solution of benzoyl chloride (37.8 ml, 0.327 mol) in anhydrous pyridine (100 ml) was added dropwise and the reaction mixture was stirred at 0°C for 45 min. Then the reaction was quenched with water (5 ml) and the mixture was partially concentrated under reduced pressure and diluted in methylene chloride (500 ml). The organic layer was washed with a saturated aqueous sodium hydrogencarbonate solution (2 × 300 ml), with water (2 × 300 ml) and then dried over sodium sulfate and evaporated under reduced pressure. The residue was purified by silica gel column chromatography 
To a solution of 2 (69.0 g, 0.23 mol) in dry pyridine (800 ml) under argon atmosphere were added tert-butyldimethylsilyl chloride (53.0 g, 0.35 mol) and imidazole (40.0 g, 0.59 mol), and the mixture was stirred at 30°C for 24 h. Then the reaction was quenched with 10% aqueous sodium hydrogencarbonate solution (10 ml), partially concentrated under reduced pressure and diluted in chloroform (500 ml). The organic layer was washed with a 10% aqueous sodium hydrogencarbonate solution (2 × 300 ml), with water (2 × 300 ml) and then dried over sodium sulfate and evaporated under reduced pressure. The residue was purified by silica gel column chromatography (eluent: stepwise gradient of methanol, 0-8% in chloroform) to give pure 3 (96.6 g, quantitative) as a colorless syrup. 
4-C-(Hydroxymethyl
Dicyclohexylcarbodiimide (DCC; 50.3 g, 0.24 mol) and dichloroacetic acid (4 ml, 48.7 mmol) were added to a solution of 4 (49.5 g, 0.16 mol) in anhydrous benzene (490 ml), DMSO (325 ml) and pyridine (13 ml). The resulting solution was stirred at room temperature under argon atmosphere for 23 h and diluted with ethyl acetate (650 ml). Oxalic acid (2.3 g, 25.5 mmol) dissolved in DMSO (30 ml) was added and the reaction mixture was stirred at room temperature during 1 h and then filtered to eliminate precipitated dicyclohexylurea (DCU). The filtrate was washed with brine (2 × 500 ml), with a saturated aqueous sodium hydrogencarbonate solution (2 × 500 ml) and finally with water (3 × 500 ml) before 
To an ice-cold solution of 6 (26.8 g, 0.12 mol) in dry THF (730 ml) was added portionwise under argon sodium hydride (60% dispersion in mineral oil, 29.2 g, 0.73 mol), and the reaction mixture was stirred for 15 min under argon atmosphere. Solid tetrabutylammonium iodide (2.7 g, 7.3 mmol) was added to the reaction mixture, followed by a dropwise addition of benzyl bromide (72.4 ml, 0.61 mmol). The reaction mixture was stirred at room temperature for 24 h under argon atmosphere. After addition of methanol (25 ml), the solution was partially concentrated under reduced pressure and diluted with methylene chloride (500 ml). The organic layer was washed with brine (2 × 400 ml), with water (400 ml) and then dried over sodium sulfate and evaporated under reduced pressure. 
Methyl 3,5-Di-O-benzyl-4-C-[(benzyloxy)methyl]-α,β-D-threo-pentofuranoside (8)
To an ice-cold solution of 7 (53.2 g, 92 mmol) in 85% acetic acid (185 ml) was added concentrated sulfuric acid (0.75 ml, 13.8 mmol). The temperature was raised to 50°C and the reaction was stirred at this temperature during 3.5 h. Then the reaction mixture was cooled in an ice-cold bath, diluted with water (100 ml) and neutralized with solid sodium hydrogencarbonate. The organic layer was extracted with chloroform (2 × 300 ml) and the combinated extracts were successively washed with a saturated aqueous sodium hydrogencarbonate solution (2 × 400 ml) and finally with water (2 × 400 ml) before being dried over sodium sulfate and evaporated to dryness. The resulting crude residue was dissolved in dry methanol (550 ml) and cooled to 0°C. To this ice-cold solution was added concentrated sulfuric acid (1.5 ml, 27.6 mmol) and the reaction was strirred at room temperature during 23 h, then neutralized with pyridine, concentrated under reduced pressure and diluted with methylene chloride (300 ml). The organic layer was washed with water (2 × 300 ml) before being dried over sodium sulfate and evaporated to dryness. The resulting residue was purified by silica gel column chromatography (eluent: chloroform/methanol, 0.5%) to give pure 8 as a pale yellow syrup (40.6 g, 95%) as a~1:2 α:β mixture. 1 
Methyl 2,3,5-Tri-O-benzyl-4-C-[(benzyloxy)methyl]-α,β-D-threo-pentofuranoside (9)
To an ice-cold solution of 8 (10.2 g, 22.0 mmol) in dry THF (180 ml) was added portionwise under argon sodium hydride (60% dispersion in mineral oil, 2.63 g, 65.9 mol), and the reaction mixture was stirred for 15 min under argon atmosphere. Solid tetrabutylammonium iodide (162 mg, 0.44 mmol) was added to the reaction mixture followed by a dropwise addition of benzyl bromide (6.5 ml, 54.9 mmol). The reaction mixture was stirred at room temperature for 22 h under argon atmosphere. After the addition of methanol (9 ml), the solution was partially concentrated under reduced pressure and diluted with methylene chloride (400 ml). The organic layer was washed with brine (2 × 300 ml), with water (1 × 400 ml) and then dried over sodium sulfate and evaporated under reduced pressure. The residue was purified by silica gel column chromatography (eluent: stepwise gradient of chloroform, 70-100% in hexanes) and then a stepwise gradient of methanol (0-1%) in chloroform to give pure 9 as a pale yellow syrup (11.3 g, 92%) as a~1:2 α:β mixture. 
1-O-Acetyl-2,3,5-tri-O-benzyl-4-C-[(benzyloxy)methyl]-α,β-D-threo-pentofuranose (10)
An ice-cold 90% aqueous trifluoroacetic acid solution (51 ml) was added to 9 (9.5 g, 17.1 mmol) and the reaction mixture was stirred between 3 and 10°C for 4.5 h and at room temperature for 1.5 h. Then the reaction mixture was cooled in an ice-cold bath, diluted with water (50 ml) and neutralized with solid sodium hydrogencarbonate. The organic layer was extracted with chloroform (2 × 150 ml) and the combined extracts were successively washed with a saturated aqueous sodium hydrogencarbonate solution (2 × 200 ml) and finally with water (2 × 200 ml) before being dried over sodium sulfate and evaporated to dryness. The resulting residue was co-evaporated twice with anhydrous pyridine and diluted in this solvent (120 ml). To the solution was added acetic anhydride (16.2 ml, 171.3 mmol) and the reaction was stirred at room temperature during 5 h, then partially concentrated under reduced pressure and diluted with methylene choride (300 ml). The organic layer was successively washed with a saturated aqueous sodium hydrogencarbonate solution (2 × 200 ml) and finally with water (2 × 200 ml) before being dried over sodium sulfate and evaporated to dryness and co-evaporated with toluene. The crude material was purified by silica gel column chromatography (eluent: stepwise gradient of chloroform, 70-100% in hexanes) to give pure 10 as a pale yellow syrup (8.1 g, 80%) as a 3:1 α:β mixture. A mixture of uracil (276 mg, 2.46 mmol), hexamethyldisilazane (HMDS; 16 ml) and a catalytic amount of ammonium sulfate was heated during 18 h under reflux. After cooling to room temperature, the mixture was evaporated under reduced pressure, and the residue obtained as a colorless oil was diluted with anhydrous 1,2-dichloroethane (17 ml). To the resulting solution was added 10 (0.99 g, 1.70 mmol) in anhydrous 1,2-dichloroethane (10 ml), followed by addition of trimethylsilyl trifluoromethanesulfonate (TMSTf, 0.62 ml, 3.40 mmol). The solution was stirred at room temperature for 2.5 h under argon atmosphere, then diluted with chloroform (150 ml), washed with the same volume of a saturated aqueous sodium hydrogencarbonate solution and finally with water (2 × 100 ml). The organic phase was dried over sodium sulfate, then evaporated under reduced pressure. The resulting crude material, as a 1.8:1 α:β mixture, was purified by silica gel column chromatography (eluent: chloroform/methanol, 0.5%) to afford as pale yellow foams pure 11␤ (295 mg, 27%), followed by a mixture of 11␣ and 11␤ (134 mg, 12%) and pure 11␣ (550 mg, 51%). 
1-[4-C-(Hydroxymethyl)-β-D-threo-pentofuranosyl]uracil (12␤)
A mixture of 11␤ (280 mg, 0.441 mmol) and 67 mg of 10% Pd/C in a 1:1 solution of methanol/acetic acid (13 ml) was hydrogenated at room temperature and atmospheric pressure during 2 days. The mixture was filtered through a pad of Celite and the filtrate was concentrated under reduced pressure. The crude material was purified by silica gel column chromatography (eluent: stepwise gradient of methanol, 10-20% in chloroform) to give pure 12␤ (90 mg, 74%), which was recrystallized from ethanol, m.p. 
1-[4-C-(Hydroxymethyl)-α-D-threo-pentofuranosyl]uracil (12␣)
Hydrogenation of 11␣ (534 mg, 0.841 mmol) was performed following the same procedure as described for the deprotection of compound 11␤, and provided, after purification by silica gel chromatography, pure 12␣ (218 mg, 94%), which was precipitated from a metha- 
1-[4-C-(Hydroxymethyl)-β-D-threo-pentofuranosyl]thymine (14␤)
Hydrogenation of 13␤ (213 mg, 0.328 mmol) was performed following the same procedure as described for the deprotection of compound 11␤, and provided, after purification by silica gel chromatography, pure 14␤ (90 mg, 95%), which was lyophilized, m.p. 92-98°C. UV 
4′-C-(Hydroxymethyl)nucleosides
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1-[4-C-(Hydroxymethyl)-α-D-threo-pentofuranosyl]thymine (14␣)
Hydrogenation of 13␣ (309 mg, 0.476 mmol) was performed following the same procedure as described for the deprotection of compound 11␤, and provided, after purification by silica gel chromatography, pure 14␣ (125 mg, 91%), which was lyophilized from water, m.p. 
Hydrogenation of 15␤ (215 mg, 0.329 mmol) was performed following the same procedure as described for the deprotection of compound 11␤, and provided, after purification by silica gel chromatography, 16␤ (92 mg, 96%), which was lyophilized from water, m.p. 
1-[4-C-(Hydroxymethyl)-β-D-threo-pentofuranosyl]cytosine (18␤)
A solution of 17␤ (250 mg, 0.394 mmol) in anhydrous dichloromethane (4 ml) was treated at -78°C under argon with a 1 M boron trichloride solution in dichloromethane (6.3 ml).
After stirring at -78°C for 3 h and at -25°C overnight, the reaction mixture was cooled at -78°C, a 1:1 mixture of anhydrous methanol and pyridine was added dropwise and the solution was evaporated to dryness. A mixture of 15␣ and 15␤ (273 mg, 0.418 mmol) was treated with Lawesson's reagent (118 mg, 0.293 mmol) in anhydrous 1,2-dichloroethane (10.5 ml), following the same procedure as described for the thionation of compound 11␤, and provided the corresponding 4-thio intermediates, which were treated with methanolic ammonia following the same procedure as described above to give, after several purifications by silica gel chromatography (eluent: stepwise gradient of methanol, 2-3% in chloroform), pure 19␤ (100 mg, 42%), a mixture of 19␣ and 19␤ (7 mg, 3%), and pure 19␣ (130 mg, 55%). Both compounds were pale yellow foams.
reflux. To the resulting solution was added at 0°C 10 (0.99 g, 1.70 mmol) in anhydrous acetonitrile (18.5 ml), followed by addition of tin(IV) chloride (0.795 ml, 6.80 mmol). The solution was stirred at room temperature for 7 h under argon atmosphere. To the reaction mixture was added carefully a saturated aqueous sodium hydrogencarbonate solution (7 ml) and the resulting mixture was filtered through a sintered funnel covered with Celite. The Celite was then triturated and washed several times with boiling chloroform (100 ml). The combined filtrates were concentrated under reduced pressure and the resulting residue was diluted with chloroform (150 ml), washed with water (3 × 100 ml). The organic layer was dried over sodium sulfate and evaporated under reduced pressure. Column chromatography of the residue using a stepwise gradient of ethyl acetate (20-40%) in hexanes afforded 6-chloro-7-{2,3,5-tri-O-benzyl-4-C-[(benzyloxy)methyl]-α-and -β-D-threo-pentofuranosyl}-purines 21␣ and 21␤ (2.02 g, 48%), and 22␣ and 22␤ (1.07 g, 26%). To a solution of 21␣ and 21␤ (2.02 g, 2.98 mmol) in anhydrous acetonitrile (20 ml) was added at 0°C trimethylsilyl trifluoromethanesulfonate (TMSOTf; 0.864 ml, 4.77 mmol). The solution was stirred at room temperature for 1.5 h under argon atmosphere, then diluted with chloroform (150 ml), washed with the same volume of a saturated aqueous sodium hydrogencarbonate solution, with brine (2 × 100 ml) and finally with water (1 × 100 ml). The organic phase was dried over sodium sulfate, then evaporated under reduced pressure. Column chromatography of the residue using a stepwise gradient of ethyl acetate (20-40%) in hexanes afforded 22␣ and 22␤ (1.09 g, 54%). Anomeric purification of the combined material obtained above as a 0.8:1 α:β mixture was performed by silica gel chromatography (eluent: hexanes/ethyl acetate, 8:2) and afforded as pale yellow foams pure 22␤ (1.00 g, 48%), a mixture of 22␣ and 22␤ (0.29 g, 14%), and pure 22␣ (0.81 g, 39%). Compound 22␤ (0.98 g, 1.45 mmol) was treated with ethanolic ammonia (29 ml previously saturated at -10°C and tightly stoppered) at 75°C in a stainless-steel bomb for 5.5 h, then cooled to room temperature. The solution was evaporated to dryness under reduced pressure. The resulting residue was diluted with chloroform (150 ml) and the organic layer was washed with brine (3 × 150 ml), dried over sodium sulfate and evaporated to dryness. The crude residue was purified by silica gel column chromatography (eluent: stepwise gradient of methanol, 0-4% in chloroform) to give pure 23␤ as a pale yellow foam (782 mg, 82%). 
